Abstract
e14512 Background: Unresectable BTC has a poor prognosis. Systemic chemotherapy with gemcitabine and cisplatin is an effective treatment option as recently demonstrated but with systemic side effects. Tumour growth in these patients (pts) is often restricted to liver, so HAI may be considered. Methods: In consecutive pts with histologically confirmed advanced inoperable BTC without relevant distant metastases catheters were interventionally placed in A. hep. via A. fem. sup. and connected to a port chamber on the front of the tight. HAI of 5FU 600 mg/mq/2h combined with FA 170 mg/mq/2h followed by O 85 mg/mq/2h were given every 2 weeks. Pts were followed prospectively with regard to port complications, response rate, TTP and OS. Results: By end of December 2009, 37 pts (15 men; 13 after partial liver resection; 6 after systemic chemotherapy) were included. Median age was 62 years (range 41-79), median follow up is 9.5 months, median treatment duration 6.2 months (0.5-22.7). III° toxicity occured in 9 pts (1 diarrhea, 1 PNP, 1 nausea, 2 leukopenia, 4 thrombopenia). 9 pts developed manageable port complications (3 thrombosis, 4 dysfunction, 1 malposition, 1 arterial spasm). End of treatment was due to tumour progression in 29 pts, to port complication (infection) preceding PD in 2 pts. 7 pts developed intra-hepatic progression, 5 showed new extra-hepatic metastases and 17 both. There were 6 PR and 18 SD. Median TTP was 6.4 months (0.5-26.0). Median OS was 10.0 months (0.9-49.0+), 1year-survival 43%. Conclusions: In pts with BTC restricted to the liver, HAI is a promising treatment approach. Prolonged HAI chemotherapy with oxaliplatin, 5-FU/FA is feasible and well tolerated. Author Disclosure Employment or Leadership Position Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, C.R. BARD, Cook, Fresenius Biotech, GlaxoSmithKline, Lilly, Merck, Pfizer, Roche, sanofi-aventis Amgen, Merck, Roche, sanofi-aventis
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
